Fannie Mae, Freddie Mac shares tumble after conservatorship comments
BOTHELL, WA—Todd Berard, the Chief Marketing Officer of BioLife Solutions Inc. (NASDAQ:BLFS), a company with a market capitalization of $1.05 billion and strong liquidity position, recently sold a portion of his holdings in the company. According to InvestingPro data, the company maintains a healthy current ratio of 4.73, indicating robust financial stability. According to a filing with the Securities and Exchange Commission dated May 28, 2025, Berard sold 348 shares of BioLife Solutions’ common stock at a price of $22.46 per share. The total value of the transaction amounted to $7,816. The stock currently trades at $21.87, slightly below the transaction price, with InvestingPro analysis indicating the stock is fairly valued based on its proprietary Fair Value model.
Following this sale, Berard retains ownership of 135,284 shares in the company. The transaction was executed under a Rule 10b5-1 trading plan, which Berard had adopted to meet tax withholding obligations related to the vesting of restricted stock. For deeper insights into insider trading patterns and comprehensive financial analysis, including 7 additional ProTips, access the full BioLife Solutions research report on InvestingPro.
In other recent news, BioLife Solutions reported its Q1 2025 earnings, surpassing expectations with an earnings per share (EPS) of -$0.01, compared to the forecast of -$0.05. The company’s revenue reached $23.9 million, exceeding the anticipated $21.6 million, marking a 30% year-over-year increase. BioLife Solutions provided full-year revenue guidance of $95.5 million to $99 million, with significant contributions expected from its cell processing platform. Additionally, H.C. Wainwright maintained a Buy rating for BioLife Solutions, setting a price target of $30.00 per share and expressing confidence in the company’s revenue growth trajectory. The firm updated its financial model to reflect expected growth in 2025, excluding discontinued operations. BioLife’s management has projected Cell Processing revenue to range between $86.5 million and $89.0 million in 2025, while evo and Thaw products are expected to contribute between $9.0 million and $10.0 million. These recent developments reflect a positive outlook for BioLife Solutions as it continues to achieve its projected revenue targets.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.